Clinical Trials Logo
  1. Home
  2. Pseudomyxoma Peritonei
  3. NCT04982146

Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei

Pseudomyxoma Peritonei Clinical Trial

Official title:
Intratumoral Bromelain + N-acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei. Phase I Single-arm Trial

Clinical Trial Summary

This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04982146
Study type Interventional
Source Maimónides Biomedical Research Institute of Córdoba
Contact
Status Active, not recruiting
Phase Phase 1
Start date September 13, 2021
Completion date May 16, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04024917 - Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis N/A
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Active, not recruiting NCT01427101 - Results of CRS and Debulking in PMP Patients N/A
Completed NCT04088786 - Phase I Trial HIPEC With Nal-irinotecan Phase 1
Not yet recruiting NCT06084780 - Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Phase 2
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Withdrawn NCT04125225 - What Are the Experiences of Patients With Pseudomyxoma Peritonei?
Not yet recruiting NCT03976973 - BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Completed NCT05513183 - Severe Neutropenia After HIPEC Using Mitomycin-C
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT03210298 - International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Active, not recruiting NCT02387203 - Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Phase 2
Terminated NCT04665921 - A Study of SGN-STNV in Advanced Solid Tumors Phase 1
Recruiting NCT05321329 - Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients Phase 2